Evidence map›Paper›PMID 37898545›Full record

ArticleGut2024

CD39 deletion in TCR-engineered T cells enhances antitumour immunity.

Alexander K Tsai, Ingunn M Stromnes

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Targeting CD39 as a Therapeutic for Cancer Immunotherapy.Expert reviews in molecular medicine · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alexander K TsaiMicrobiology & Immunology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-4014-1946
Ingunn M StromnesMicrobiology & Immunology, University of Minnesota, Minneapolis, Minnesota, USA ingunn@umn.edu.ORCID 0000-0001-8120-4547
University of Minnesota · US

Funding

TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Project 3P01CA254849 · NCI · UNIVERSITY OF MINNESOTA · PI ODDE, DAVID J. · 2021 to 2025
$9.4M
TECH CoreU54CA268069 · NCI · UNIVERSITY OF MINNESOTA · PI David J. Odde · 2022 to 2026
$8.2M
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinomaR01CA249393 · NCI · UNIVERSITY OF MINNESOTA · PI STROMNES, INGUNN MARGARETE · 2021 to 2025
$2.1M
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinomaR01CA255039 · NCI · UNIVERSITY OF MINNESOTA · PI STROMNES, INGUNN MARGARETE · 2021 to 2025
$2.0M
NCI NIH HHS P01 CA254849NCI NIH HHS R01 CA249393NCI NIH HHS R01 CA255039NCI NIH HHS T32 CA009138NCI NIH HHS U54 CA268069
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD8-Positive T-LymphocytesImmunotherapyAntigens, CDApyraseHumansReceptors, Antigen, T-CellAntigens, CDApyraseCD39 antigenENTPD1 protein, humanReceptors, Antigen, T-CellCOLORECTAL CANCERIMMUNE RESPONSEIMMUNOTHERAPYT LYMPHOCYTES

Identifiers

PMID37898545
PMCPMC10997453
OpenAlexW4387999653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.